- Laboratory >
- Laboratory medicine >
- Tumor marker reagent >
- KOFA
KOFA tumor marker reagents
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
{{#each product.specData:i}}
{{name}}: {{value}}
{{#i!=(product.specData.length-1)}}
{{/end}}
{{/each}}
{{{product.idpText}}}
Storage temperature: 2 °C - 8 °C
Ready-to-use Integrated CLIA Reagent Kits Pack Size: 25 tests/kit, 50 tests/kit, 100 tests/kit, 200 tests/kit Test Menu -Fertility: FSH/LH/PRL/β-HCG/E2/PROG/TES -Tumor Markers: AFP/CEA/CA125/CA15-3/CA19-9/tPSA/fPSA/CYFRA21-1 -Cardiac ...
Guangzhou KOFA Biotechnology Co.,Ltd.
25 tests/kit, 50 tests/kit, 100 tests/kit, 200 tests/kit Glycometabolism : FER/Cortisol/C-Peptide/INS
Guangzhou KOFA Biotechnology Co.,Ltd.
AFP, CEA, CA125, CA15-3, CA19-9, tPSA, fPSA, CYFRA21-1, proGRP, NSE, PAP, SCC, CA50, CA72-4, HE4, CA242 Related disease Tumors (lung cancer, gastrointestinal cancer, pancreatic cancer, breast cancer, medullary thyroid ...
Guangzhou KOFA Biotechnology Co.,Ltd.
The CLIA reagent kit covers tumor markers, cardiac markers, hormones, thyroid function, metabolism, inflammation and other testing series, which can meet different clinical ...
Guangzhou KOFA Biotechnology Co.,Ltd.
The Biochemical reagent kit covers liver function, kidney function, blood lipid, cardiovascular, immune function, tumor marker, genetic testing and other testing series, up to 100+ test ...
Guangzhou KOFA Biotechnology Co.,Ltd.
The reagent kit is mainly used to quantitatively detect the fpSA level in human serum. For professional use only. it can notbe used as the basis for early diagnosis or diagnosis of malignant tumors, and ...
Guangzhou KOFA Biotechnology Co.,Ltd.
Your suggestions for improvement:
Receive monthly updates on this section.
Please refer to our Privacy Policy for details on how MedicalExpo processes your personal data.
- Brand list
- Manufacturer account
- Buyer account
- Our services
- Newsletter subscription
- About VirtualExpo Group
Please specify:
Help us improve:
remaining